Amy Schroeder offers strategic guidance and solutions for influencing clinical data, drug and pharmacopeial compendia, guidelines, and decision support technologies.

She covers health policy, payer coverage and reimbursement, state drug coverage legislation, and provider prescribing behaviors impacting oncology, rare diseases, and diabetes. Amy has 30 years of healthcare experience, including positions as a pharmacist and medical writer, and in drug information, payer coverage and access, and consulting. She serves as a patient advocate on the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) at CMS and on the editorial board of the Journal of Clinical Pathways.

Her clinical experience began in cancer research, followed by positions in specialty and home infusion pharmacy, leadership roles at clinical and pharmacopeial drug compendia, and industry. She contributed to the initial USP Medicare Model Guidelines, to guide Part D plans in developing and maintaining their drug formularies, and drafting Level I clinical pathways content for US Oncology. Following that, she independently consulted on the impact of clinical drug data on payer coverage and reimbursement, then became a senior consultant for Lash Group Healthcare Consultants and DK Pierce & Associates, Inc. At Resolution Health, Inc., a subsidiary analytics firm under Anthem, Inc., she was the assistant director of Clinical Pharmacy R&D, assessing alignment of claims data to evidence-based clinical guidelines, identifying cost-savings opportunities and safety concerns for members. Amy is the only pharmacist who has contributed to the content of 3 clinical drug compendia (United States Pharmacopeia Drug Information, American Hospital Formulary Service Drug Information, and the National Comprehensive Cancer Network Drugs & Biologics Compendium), recognized by CMS and commercial payers.

She has a BS in science/microbiology from the Pennsylvania State University and a BS in pharmacy from the University of Maryland School of Pharmacy. She is a licensed pharmacist and has served as a preceptor to pharmacy students.

Authored Content

Type 2 diabetes (T2D) rates have grown substantially over the years and have placed a significant burden on the US healthcare system. While prevention efforts continue to advance, including the availability of screening tools and early prevention therapies, systemic disparities still preclude equitable access to preventive services. These will need to be addressed as a key component of strengthening patient access to preventive care and lowering the incidence of disease.

Avalere analysis found that in 2017 and 2018, more than half (56%) of Medicare patients with breast cancer taking a medicine covered by Medicare Part B received a therapy that was not routinely covered by England’s National Health Service (NHS) or its Cancer Drug Fund (CDF).

Tune into another episode of Start Your Day with Avalere. In this segment, experts from Avalere’s Market Access continue their discussion on clinical pathways in oncology, exploring how they are developed and what cancers and treatment modalities are included.

Tune into another episode of Start Your Day with Avalere. In this segment, experts from Avalere’s Market Access practice discuss clinical pathways as they relate to value in oncology.

In this third episode, Sam Ferguson, a consultant in Avalere’s Market Access practice, along with Allison Petrilla, a managing director in Avalere’s Health Economics and Advanced Analytics practice, and Amy Schroeder, a senior consultant in Avalere’s Market Access practice, discuss how stakeholders are utilizing and translating real-world evidence (RWE) into value for oncology.

As COVID-19 deaths increase, the FDA is evaluating and considering approval of treatments more quickly, but the rush to find treatment options is creating new access considerations for patients and providers.

On Saturday, December 7, Karl Kilgore discussed “Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs” during a press briefing at the American Society of Hematology’s Annual Meeting.